Stein Rune Kjelby

Stein Rune Kjelby has a diverse work experience in various finance and accounting roles. Stein Rune started their career at Ernst & Young as a Senior Assurance and Business Advisor, where they gained valuable experience in auditing and advising businesses. Stein Rune then moved on to Dynal Biotech ASA as a Controller, managing financial operations. Kjelby furthered their career at Invitrogen Dynal AS (now Life Technologies) as a Senior Financial Analyst, analyzing financial data and providing insights. Stein Rune then joined NorDiag ASA as a Chief Accountant, where they contributed to the development and marketing of automated solutions for sample preparation. Kjelby later became the Vice President of Finance and Administration at NORDA ASA (formerly NorDiag ASA), overseeing financial operations and participating in the biotechnology sector. Stein Rune then worked as a Consultant at Fabi, offering their expertise in financial and strategic consulting. Currently, Kjelby holds the position of Head of Accounting at Nordic Nanovector ASA, a company focused on developing innovative treatments for haematological cancers. Their role involves financial management and contributing to the commercialization of new products. Overall, Kjelby has a strong background in finance and accounting, with experience in both biotechnology and consulting industries.

From 1996 to 2000, Stein Rune Kjelby attended the Norwegian School of Economics (NHH) where they pursued a M.Sc. in Economics and Business Administration (Siviløkonom). Their area of focus during this program was Accounting and Financial Management.